Catalyst Pharmaceutical Partners, Inc. (CPRX) Announces Recommendation of Data Monitoring Committee to Continue Pivotal Phase 3 Clinical Trial for Firdapse
10/15/2013 9:26:01 AM
CORAL GABLES, Fla., Oct. 15, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders, announced today that, at a recently held meeting, the independent Data Monitoring Committee (DMC) overseeing the Company's ongoing pivotal Phase III clinical trial in the United States and Europe evaluating Firdapse™ for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) recommended that the Company continue the trial as planned based on the committee's review of safety and clinical data from the trial.
Help employers find you! Check out all the jobs and post your resume.
comments powered by